



Attorney Docket No. 56422-C (45487)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Bjarne Due LARSEN, et al.

U.S.S.N.: 10/646,294

Group Art Unit: Not yet assigned

FILED: August 22, 2003

Examiner: Not yet assigned

FOR: NEW MEDICAL USES OF INTERCELLULAR COMMUNICATION
FACILITATING COMPOUNDS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on January 27, 2004.

By: Patricia A. Barnes
Patricia A. Barnes

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date: January 27, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed. References BA, CA-CD on Sheet 1 were considered in the parent case USSN 09/792,286, filed on 02/22/01 and copies are enclosed with this submission.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In

the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
or
- b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my


knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,


Date: 27 JAN 2004



Robert L. Buchanan, (Reg. No. 40,927]
EDWARDS & ANGELL, LLP.
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748

Customer No.: 21874

#430505



FORM PTO-1449		DOCKET NO: 56422-C. (45487)		SERIAL NO.: 10/646,294			
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Bjarne Due Larsen, et al.					
		FILING DATE: August 22, 2003		GROUP NO.: Not yet assigned			
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	0 214 659 A	18. 03.87	Europe			Y
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	CA	Y. Kohama, et al. "Effect of N-3-(4-Hydroxyphenyl) propionyl Pro-Pro-Gly-Ala-Gly on Calcium-Induced Arrhythmias", CHEMICAL & PHARMACEUTICAL BULLETIN, Vol. 36, No. 11, 1988, pp. 4597-4599.					
	CB	S. Dhein, et al. "Therapeutic Potential of Antiarrhythmic Peptides", DRUGS, Vol. 49, No. 6, 1995, pp. 851-855.					
	CC	B. Kundu "Synthesis, conformational features and biological activity of Pro-3 antiarrhythmic peptide", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, Vol. 54, No. 3, 1989, pp. 760-771.					
	CD	B. Weinstein "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins" 1982, MARCEL DEKKER INC., NEW YORK AND BASEL, page 357.					
EXAMINER:					DATE:		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Bjarne Due LARSEN, et al.

U.S.S.N.: 10/646,294

EXAMINER: Not yet assigned

FILED: August 22, 2003

GROUP: Not yet assigned

FOR: NEW MEDICAL USES OF INTERCELLULAR COMMUNICATION
FACILITATING COMPOUNDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

.....
CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 27, 2004.

By: Patricia A. Barnes
Patricia A. Barnes

.....
CHANGE OF ATTORNEY'S MAILING ADDRESS IN APPLICATION

Applicant requests that all further communications from the Patent and Trademark Office in connection with the subject application be sent to the following address:

**Edwards & Angell, LLP
Intellectual Property Practice Group
P.O. Box 55874
Boston, MA 02205
Tel.: (617) 439-4444
Facsimile: (617) 439-4170**

Respectfully submitted,

Date: 27 Jan 2004

By: Robert L. Buchanan
Robert L. Buchanan
Reg. No. 40,927
Customer No.: 21874